Researchers discover that SLC2A9 is a high-capacity urate transporter in humans

An international team of researchers led by Professors Mark Caulfield and Patricia Munroe, from the William Harvey Research Institute at Barts and The London School of Medicine and Dentistry with Chris Cheeseman at the University of Alberta in Canada and Kelle Moley at the University of Washington in USA, have shown that the SLC2A9 gene, which encodes a glucose transporter, is also a high-capacity urate transporter, and thus possibly a new drug target for gout. Their findings are published in this week's PLoS Medicine (7 October 2008).

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news142565069.html">Researchers discover that SLC2A9 is a high-capacity urate transporter in humans</a></p> <p>An international team of researchers led by Professors Mark Caulfield and Patricia Munroe, from the William Harvey Research Institute at Barts and The London School of Medicine and Dentistry with Chris Cheeseman at the University of Alberta in Canada and Kelle Moley at the University of Washington in USA, have shown that the SLC2A9 gene, which encodes a glucose transporter, is also a high-capacity urate transporter, and thus possibly a new drug target for gout. Their findings are published in this week's <I>PLoS Medicine</I> (7 October 2008).</p>